{"id":3922,"date":"2026-07-29T05:13:26","date_gmt":"2026-07-29T05:13:26","guid":{"rendered":"https:\/\/education.mirrorplasticsurgery.com\/uncategorized\/semaglutide-psoriasis-2026\/"},"modified":"2026-09-09T05:17:10","modified_gmt":"2026-09-09T05:17:10","slug":"semaglutide-psoriasis-2026","status":"publish","type":"post","link":"https:\/\/www.mirrorplasticsurgery.com\/education\/peptides\/semaglutide-psoriasis-2026","title":{"rendered":"Semaglutide for Psoriasis: What the Evidence Shows"},"content":{"rendered":"

Written by: Dr. Akash Chandawarkar, Board Certified Plastic Surgeon, Mirror Plastic Surgery | Last updated: September 9, 2026<\/em><\/p>\n

Executive Summary: What This Report Finds<\/h2>\n

This report reviews clinical evidence through mid-2026, including a 2025 open-label randomized trial, a 2026 real-world cohort study of 94 patients, and the National Psoriasis Foundation’s 2026 primer in JAMA Dermatology<\/a>. Semaglutide shows meaningful potential to improve psoriasis, especially in patients who also have excess weight or type 2 diabetes, yet it remains an off-label option that requires careful medical oversight.1<\/sup><\/p>\n

Our practice offers medically supervised peptide therapy, including semaglutide and other GLP-1 receptor agonists, for patients who want an integrated approach to metabolic and inflammatory health under the direct care of our board-certified plastic surgeon.<\/p>\n

Schedule a consultation<\/a> to see whether a supervised semaglutide protocol fits your health profile.<\/strong><\/p>\n

Evidence Review Approach for This Report<\/h2>\n

This report draws on peer-reviewed clinical studies identified through systematic searches of PubMed and Scopus, the 2026 systematic review by Marani et al. in the Journal of Clinical Medicine<\/a> analyzing 26 studies, the National Psoriasis Foundation Medical Board primer in JAMA Dermatology, and real-world pharmacovigilance data. Evidence quality ranges from randomized trials to case reports, and findings are weighed accordingly throughout this report.<\/p>\n

This structured approach separates the analysis from anecdotal social media content and from older clinical literature that predates the pivotal 2025\u20132026 evidence base.<\/p>\n

How Semaglutide Connects Metabolic Health and Psoriasis<\/h2>\n

Psoriasis is a chronic immune-mediated inflammatory disease driven by cytokines including IL-17, IL-23, and TNF-\u03b1. Obesity and type 2 diabetes amplify systemic inflammation, because adipose tissue acts as an immunologically active organ that produces pro-inflammatory cytokines. This heightened inflammatory state worsens psoriatic disease activity and can reduce the effectiveness of biologic therapies.<\/p>\n

GLP-1 receptors have been identified in psoriatic plaques but not in unaffected skin<\/a>, which suggests a potential direct role in lesional immune responses. Semaglutide operates through a dual mechanism. It reduces inflammatory markers such as IL-6 and C-reactive protein (CRP), and it produces weight loss that lessens the overall inflammatory burden.<\/p>\n

GLP-1 receptor activation suppresses NF-\u03baB, JAK2\/STAT3, and SOCS3 signaling in keratinocytes through AMPK activation<\/a>, which reduces secretion of pro-inflammatory cytokines such as TNF-\u03b1 and IL-6. In addition, GLP-1 receptor agonists modulate the IL-23\/Th17\/IL-17 axis<\/a>, a central inflammatory pathway in psoriasis, by reducing dermal \u03b3\u03b4 T-cell numbers and IL-17 expression in psoriatic skin.<\/p>\n

Key Finding #1: Semaglutide Improves Psoriasis Severity<\/h2>\n

The strongest evidence comes from four sources published in 2025\u20132026.<\/p>\n

First, the 2025 open-label randomized trial by Petkovi\u0107-Dabi\u0107 et al.<\/a> enrolled 31 patients with psoriasis, obesity, and type 2 diabetes. Median PASI improved from 21 to 10 and DLQI from 14 to 4.1<\/sup> Among the 15 semaglutide-treated patients, 13 achieved PASI90 and one achieved PASI100 after 12 weeks.1<\/sup><\/p>\n

Building on this, the 2026 retrospective cohort study by Bar et al. at Sheba Medical Center<\/a> found that 44.4% of GLP-1-treated patients achieved clear or almost-clear skin (IGA 0\/1) at 48 weeks versus 12.1% of controls (P < .001).1<\/sup> Among patients receiving both a GLP-1 and a biologic, 85.0% achieved IGA 0\/1 compared with 52.5% on biologics alone (P = .029).1<\/sup> Semaglutide-specific analysis showed an adjusted odds ratio of 3.12 for achieving IGA 0\/1.1<\/sup><\/p>\n

In parallel, the 2026 systematic review by Marani et al.<\/a> analyzed 26 studies and reported substantial PASI reductions across semaglutide studies.1<\/sup> The National Psoriasis Foundation’s 2026 JAMA Dermatology primer<\/a> similarly found GLP-1 receptor agonists associated with 40\u201380% PASI reductions in patients with psoriasis.1<\/sup><\/p>\n

Key findings from the 2025\u20132026 evidence base include the following:<\/p>\n